| News

Roivant developing treatment for coronavirus patients

23.03.2020

The Basel-based pharmaceutical company Roivant Sciences wants to develop a special antibody for coronavirus patients. This is intended to help treat and prevent acute respiratory distress syndrome.

Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences
Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences

Roivant Sciences is working on the development of a monoclonal antibody by the name of gimsilumab, as detailed in a press release. This targets the cytokine GM-CSF. According to the company, new clinical evidence is revealing that there is a connection between GM-CSF and acute respiratory distress syndrome (ARDS) in coronavirus patients. ARDS is a serious complication related to coronavirus that can see patients hospitalized or necessitate the use of mechanical ventilation or other life-support measures.

Roivant Sciences has previously tested gimsilumab in non-clinical investigations as part of a Phase 1 study. Treatment with the antibody has so far “been associated with a favorable safety and tolerability profile”, the press release states. The company has now contacted the regulatory authorities in the USA, Europe and Asia, with the aim of driving forward the clinical development of this antibody.

“Targeting GM-CSF represents a promising strategy for curbing lung damage while allowing time for the virus to clear”, comments Elizabeth Volkmann from the US institute UCLA Health, in the press release. “It is my hope that gimsilumab will reduce mortality from COVID-19 and help improve the lives of those affected by this emerging public health crisis”, she explains further.

Roivant Sciences and its subsidiaries received support from BaselArea.swiss during their efforts to establish a presence in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
Lumineo installs translucent concrete wall for Vinci
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Lumineo installs translucent concrete wall for Vinci

The global construction and energy group Vinci engaged the jurassic Lumineo Group to design a wall made from translucent concrete...

Read More
Roivant invests 200 million dollars in Immunovant
Basel Area Business & Innovation, Innovation, Invest

Roivant invests 200 million dollars in Immunovant

The Basel-based Roivant Group has invested a total of 200 million dollars in the US biopharmaceutical company Immunovant. This investment...

Read More
Lyfegen collaborating with Johnson & Johnson
Basel Area Business & Innovation, Innovation, Invest

Lyfegen collaborating with Johnson & Johnson

The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result...

Read More
Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.